nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

14.12.2023 | Short Communication

Detection of metabolic adaptation in a triple-negative breast cancer animal model with [¹⁸F]choline-PET imaging as a surrogate for drug resistance

verfasst von: Andres A. Kohan, Mathieu Lupien, David Cescon, Geneviève Deblois, Manuela Ventura, Ur Metser, Patrick Veit-Haibach

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Test the feasibility of an image-based method to identify taxane resistance in mouse bearing triple-negative breast cancer (TNBC) tumor xenografts.

Methods

Xenograft tumor-bearing mice from paclitaxel-sensitive and paclitaxel-resistant TNBC cells (MDA-MD-346) were generated by orthotopic injection into female NOD-SCID mice. When tumors reached 100–150 mm³, mice were scanned using [¹⁸F]choline PET/CT. Tumors were collected and sliced for autoradiography and immunofluorescence analysis. Quantitative data was analyzed accordingly.

Results

From fifteen mice scanned, five had taxane-sensitive cell line tumors of which two underwent taxol-based treatment. From the remaining 10 mice with taxane-resistant cell line tumors, four underwent taxol-based treatment. Only 13 mice had the tumor sample analyzed histologically. When normalized to the blood pool, both cell lines showed differences in metabolic uptake before and after treatment.

Conclusions

Treated and untreated taxane-sensitive and taxane-resistant cell lines have different metabolic properties that could be leveraged before the start of chemotherapy.

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48. https://doi.org/10.1056/NEJMra1001389.CrossRefPubMed

Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23(Suppl 6):vi46-51. https://doi.org/10.1093/annonc/mds195.CrossRefPubMed

Deblois G, Tonekaboni SAM, Grillo G, Martinez C, Kao YI, Tai F, et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer. Cancer Discov. 2020;10:1312–29. https://doi.org/10.1158/2159-8290.CD-19-1493.CrossRefPubMed

Chew YC, West JT, Kratzer SJ, Ilvarsonn AM, Eissenberg JC, Dave BJ, et al. Biotinylation of histones represses transposable elements in human and mouse cells and cell lines and in Drosophila melanogaster. J Nutr. 2008;138:2316–22. https://doi.org/10.3945/jn.108.098673.CrossRefPubMedPubMedCentral

Thomas ML, Marcato P. Epigenetic modifications as biomarkers of tumor development, therapy response, and recurrence across the cancer care continuum. Cancers (Basel). 2018;10. https://doi.org/10.3390/cancers10040101.

Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D, et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 2015;22:861–73. https://doi.org/10.1016/j.cmet.2015.08.024.CrossRefPubMedPubMedCentral

Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999;59:80–4.PubMed

Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwalla ZM. Choline metabolism-based molecular diagnosis of cancer: an update. Expert Rev Mol Diagn. 2015;15:735–47. https://doi.org/10.1586/14737159.2015.1039515.CrossRefPubMedPubMedCentral

Inazu M. Choline transporter-like proteins CTLs/SLC44 family as a novel molecular target for cancer therapy. Biopharm Drug Dispos. 2014;35:431–49. https://doi.org/10.1002/bdd.1892.CrossRefPubMed

10.

R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. URL http://www.R-project.org/

11.

Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81:303–11. https://doi.org/10.1111/j.1399-0004.2011.01809.x.CrossRefPubMed

12.

Nebbioso A, Tambaro FP, Dell’Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018;14: e1007362. https://doi.org/10.1371/journal.pgen.1007362.CrossRefPubMedPubMedCentral

13.

Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14:747–53. https://doi.org/10.1038/nrc3819.CrossRefPubMed

14.

Chapman-Rothe N, Curry E, Zeller C, Liber D, Stronach E, Gabra H, et al. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells. Oncogene. 2013;32:4586–92. https://doi.org/10.1038/onc.2012.477.CrossRefPubMed

15.

Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, et al. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell. 2017;32(221–37): e13. https://doi.org/10.1016/j.ccell.2017.07.002.CrossRef

16.

Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46:364–70. https://doi.org/10.1038/ng.2913.CrossRefPubMedPubMedCentral

17.

Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell. 2017;20(233–46): e7. https://doi.org/10.1016/j.stem.2016.11.003.CrossRef

18.

Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2013;110:E1490–9. https://doi.org/10.1073/pnas.1219992110.CrossRefPubMedPubMedCentral

19.

Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69–80. https://doi.org/10.1016/j.cell.2010.02.027.CrossRefPubMedPubMedCentral

20.

Watanabe T, Morinaga S, Akaike M, Numata M, Tamagawa H, Yamamoto N, et al. The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery. Eur J Surg Oncol. 2012;38:1051–7. https://doi.org/10.1016/j.ejso.2012.08.008.CrossRefPubMed

21.

Wein L, Loi S. Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast. 2017;34(Suppl 1):S27–30. https://doi.org/10.1016/j.breast.2017.06.023.CrossRefPubMed

22.

Yang Z, Xie Y, Liu C, Liu X, Song S, Zhang Y, et al. The clinical value of (18)F-fluoroestradiol in assisting individualized treatment decision in dual primary malignancies. Quant Imaging Med Surg. 2021;11:3956–65. https://doi.org/10.21037/qims-20-1364.CrossRefPubMedPubMedCentral

23.

Ge S, Li J, Yu Y, Chen Z, Yang Y, Zhu L, et al. Review: radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides. Molecules. 2021;26. https://doi.org/10.3390/molecules26216482.

24.

de Almeida Schirmer BG, de Araujo MR, Silveira MB, Pereira JM, Vieira LC, Alves CG, et al. Comparison of [(18)F]fluorocholine and [(18)F]fluordesoxyglucose for assessment of progression, lung metastasis detection and therapy response in murine 4T1 breast tumor model. Appl Radiat Isot. 2018;140:278–88. https://doi.org/10.1016/j.apradiso.2018.07.032.CrossRefPubMed

25.

Linden HM, Dehdashti F. Novel methods and tracers for breast cancer imaging. Semin Nucl Med. 2013;43:324–9. https://doi.org/10.1053/j.semnuclmed.2013.02.003.CrossRefPubMed

26.

Ahmad Saad FF, Zakaria MH, Appanna B. PET/CT analysis of 21 patients with breast cancer: physiological distribution of (18)F-choline and diagnostic pitfalls. J Int Med Res. 2018;46:3138–48. https://doi.org/10.1177/0300060518773019.CrossRefPubMedPubMedCentral

Titel: Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance
verfasst von: Andres A. Kohan
Mathieu Lupien
David Cescon
Geneviève Deblois
Manuela Ventura
Ur Metser
Patrick Veit-Haibach
Publikationsdatum: 14.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2024
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06546-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Detection of metabolic adaptation in a triple-negative breast cancer animal model with [¹⁸F]choline-PET imaging as a surrogate for drug resistance

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy

Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance

Comparative assessment of radiation therapy–induced vasculitis using [18F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy

Advances in targeted alpha therapy of cancer

Dynamic total-body PET/CT imaging with reduced acquisition time shows acceptable performance in quantification of [18F]FDG tumor kinetic metrics

FDG-PET/CT for investigation of pyrexia of unknown origin: a cost of illness analysis